Clinical Trial

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Name: Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL — clinical trial record (NCT03937544)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2019-05-01; most recent amendment 2025-05-22.

Trial Details

NCT Number	NCT03937544
Lead Sponsor	National University of Malaysia Collaborators: Gaia Science
Conditions	Relapsed B Acute Lymphoblastic Leukaemia, Refractory B Acute Lymphoblastic Leukaemia
Enrollment	10 participants
Start Date	2019-03-19
Primary Completion	2027-01-18 (estimated)
Study Completion	2027-03-18 (estimated)
Updated on ClinicalTrials.gov	2025-05-29